CTLA4 and metastatic colorectal cancer: For example, a trial of anti-PD-1 and anti-CTLA4 therapies for patients with MSS, metastatic colorectal cancer reported improved response rates for patients without liver metastases than for patients with liver metastases (57% vs. 0%, respectively; ref. 27).